Impact of neoadjuvant chemotherapy on survival and recurrence patterns after robot-assisted radical cystectomy for muscle-invasive bladder cancer: Results from the International Robotic Cystectomy Consortium.
bladder cancer
chemotherapy
muscle-invasive
neoadjuvant
oncological outcomes
recurrence
recurrences
robot-assisted radical cystectomy
survival
Journal
International journal of urology : official journal of the Japanese Urological Association
ISSN: 1442-2042
Titre abrégé: Int J Urol
Pays: Australia
ID NLM: 9440237
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
02
06
2021
accepted:
01
11
2021
pubmed:
20
12
2021
medline:
8
3
2022
entrez:
19
12
2021
Statut:
ppublish
Résumé
To analyze the impact of neoadjuvant chemotherapy on survival and recurrence patterns in muscle-invasive bladder cancer after robot-assisted radical cystectomy. The International Robotic Cystectomy Consortium database was reviewed to identify patients who underwent robot-assisted radical cystectomy for muscle-invasive bladder cancer between 2002 and 2019. Survival outcomes, response rates, and recurrence patterns were compared between patients who received neoadjuvant chemotherapy and those who did not. Survival distributions were estimated using Kaplan-Meier analyses and compared using the log-rank test. A total of 1370 patients with muscle-invasive bladder cancer were identified, of whom 353 (26%) received neoadjuvant chemotherapy. After a median follow-up of 27 months, neoadjuvant chemotherapy recipients had higher 3-year overall survival (74% vs 57%; log-rank P < 0.01), 3-year cancer-specific survival (83% vs 73%; log-rank P = 0.03), and 3-year relapse-free survival (64% vs 48%; log-rank P < 0.01). Neoadjuvant chemotherapy was a predictor of higher overall survival, cancer-specific survival, and relapse-free survival in univariate but not multivariate analysis. Pathological downstaging (46% vs 23%; P < 0.01), complete responses (24% vs 8%; P < 0.01), and margin negativity (95% vs 91%; P < 0.01) at robot-assisted radical cystectomy were more common in the neoadjuvant chemotherapy group. Neoadjuvant chemotherapy recipients had lower distant (15% vs 22%; P < 0.01) but similar locoregional (12% vs 13%; P = 0.93) recurrence rates. In this analysis from a large international database, patients with muscle-invasive bladder cancer who received neoadjuvant chemotherapy before robot-assisted radical cystectomy had higher rates of survival, pathological downstaging, and margin-negative resections. They also experienced fewer distant recurrences.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
197-205Subventions
Organisme : Roswell Park Alliance
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2021 The Japanese Urological Association.
Références
SEER Cancer stat facts: bladder cancer. 2019. [Cited 7 Dec 2021.] Available from URL: https://seer.cancer.gov/statfacts/html/urinb.html
Hautmann RE, de Petriconi RC, Pfeiffer C, Volkmer BG. Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients. Eur. Urol. 2012; 61: 1039-47.
Grossman HB, Natale RB, Tangen CM et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N. Engl. J. Med. 2003; 349: 859-66.
Galsky MD, Pal SK, Chowdhury S et al. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. Cancer 2015; 121: 2586-93.
Kubota M, Kanno T, Inoue T et al. Effect of optimal neoadjuvant chemotherapy on oncological outcomes of locally advanced bladder cancer with laparoscopic radical cystectomy: a matched-pair analysis in a multicenter cohort. Int. J. Urol. 2021; 28: 656-64.
Zaid HB, Patel SG, Stimson CJ et al. Trends in the utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer: results from the National Cancer Database. Urology 2014; 83: 75-80.
Hussein AA, Dibaj S, Hinata N et al. Development and validation of a quality assurance score for robot-assisted radical cystectomy: a 10-year analysis. Urology 2016; 97: 124-9.
Tan YG, Allen JC, Tay KJ, Huang HH, Lee LS. Benefits of robotic cystectomy compared with open cystectomy in an Enhanced Recovery After Surgery program: a propensity-matched analysis. Int. J. Urol. 2020; 27: 783-8.
Bochner BH, Dalbagni G, Marzouk KH et al. Randomized trial comparing open radical cystectomy and robot-assisted laparoscopic radical cystectomy: oncologic outcomes. Eur. Urol. 2018; 74: 465-71.
Nguyen DP, , Al Hussein Al Awamlh B, Wu X et al. Recurrence patterns after open and robot-assisted radical cystectomy for bladder cancer. Eur. Urol. 2015; 68: 399-405.
Parekh DJ, Reis IM, Castle EP et al. Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial. Lancet 2018; 391: 2525-36.
Hermans TJN, Voskuilen CS, van der Heijden MS et al. Neoadjuvant treatment for muscle-invasive bladder cancer: the past, the present, and the future. Urol. Oncol. 2018; 36: 413-22.
Vale CL. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data. Eur. Urol. 2005; 48: 202-5.
NCCN National Comprehensive Cancer Network clinical practice guidelines in oncology, Bladder Cancer, version 2.2020. 2020. [Cited 7 Dec 2021.] Available from URL: https://www.nccn.org/professionals/physician_gls/PDF/bladder.pdf
Abdollah F, Sun M, Schmitges J et al. Development and validation of a reference table for prediction of postoperative mortality rate in patients treated with radical cystectomy: a population-based study. Ann. Surg. Oncol. 2012; 19: 309-17.
Griffiths G, Hall R, Sylvester R, Raghavan D, Parmar MK. International Collaboration of Trialists Medical Research Council Advanced Bladder Cancer Working Party. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J. Clin. Oncol. 2011; 29: 2171-7.
Sonpavde G, Goldman BH, Speights VO et al. Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy. Cancer 2009; 115: 4104-9.
Weight CJ, Garcia JA, Hansel DE et al. Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder: a contemporary series. Cancer 2009; 115: 792-9.
Hinata N, Hussein AA, George S et al. Impact of suboptimal neoadjuvant chemotherapy on peri-operative outcomes and survival after robot-assisted radical cystectomy: a multicentre multinational study. BJU Int. 2017; 119: 605-11.
Hermans TJ, Fransen van de Putte EE, Horenblas S et al. Pathological downstaging and survival after induction chemotherapy and radical cystectomy for clinically node-positive bladder cancer-Results of a nationwide population-based study. Eur. J. Cancer 2016; 69: 1-8.
Zargar-Shoshtari K, Zargar H, Lotan Y et al. A multi-institutional analysis of outcomes of patients with clinically node positive urothelial bladder cancer treated with induction chemotherapy and radical cystectomy. J. Urol. 2016; 195: 53-9.
Mandel P, Tilki D, Eslick GD. Extent of lymph node dissection and recurrence-free survival after radical cystectomy: a meta-analysis. Urol. Oncol. 2014; 32: 1184-90.
Aldhaam NA, Elsayed AS, Jing Z et al. Neoadjuvant chemotherapy is not associated with adverse perioperative outcomes after robot-assisted radical cystectomy: a case for increased use from the IRCC. J. Urol. 2020; 203: 57-61.
Elsayed AS, Aldhaam NA, Brownell J et al. Perioperative and oncological outcomes of robot-assisted radical cystectomy in octogenarians. J. Geriatr. Oncol. 2020; 11: 727-30.
Wei L, Hussein AA, Ma Y et al. Accurate quantification of residual cancer cells in pelvic washing reveals association with cancer recurrence following robot-assisted radical cystectomy. J. Urol. 2019; 201: 1105-14.
Audenet F, Sfakianos JP. Evidence of atypical recurrences after robot-assisted radical cystectomy: a comprehensive review of the literature. Bladder Cancer 2017; 3: 231-6.
Khan MS, Gan C, Ahmed K et al. A single-centre early phase randomised controlled three-arm trial of open, robotic, and laparoscopic radical cystectomy (CORAL). Eur. Urol. 2016; 69: 613-21.
Hussein AA, Saar M, May PR et al. Early oncologic failure after robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. J. Urol. 2017; 197: 1427-36.
Elsayed AS, Gibson S, Jing Z et al. Rates and patterns of recurrences and survival outcomes after robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. J. Urol. 2021; 205: 407-13.
Raza SJ, Wilson T, Peabody JO et al. Long-term oncologic outcomes following robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. Eur. Urol. 2015; 68: 721-8.